Wyeth

Pfizer Corporation

Narender Kumar Kalyan

Kathrin Ute Jansen

Mark Edward Ruppen

Annaliesa Sybil Anderson

Justin Keith Moran

Robert G K Donald

Michael James Flint

Maninder K Sidhu

Jason Arnold Lotvin

Weiqiang Sun

Robert G Donald

Terri L Mininni

Robert GK Donald

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturingand in producingtoxins.

Compositions and methods relating to a mutanttoxin

In one aspect, the invention relates to an immunogenic composition that includes a mutanttoxin A and/or a mutanttoxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-typetoxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutant clostridium difficile toxin and methods thereof

In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. Each mutant toxin includes a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may further include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to antibodies or binding fragments thereof that binds to said immunogenic compositions. In further aspects, the invention relates to isolated nucleotide sequences that encode any of the foregoing, and methods of use of any of the foregoing compositions.

Compositions relating to a mutanttoxin and methods thereof

Compositions and methods relating to a mutant clostridium difficile toxin

[object Object]

Growing community of inventors

Ridgewood, NJ, United States of America

Narender Kumar Kalyan